A consecutive series of 3044 patients who underwent BMT at the University of Minnesota over a 25 year period were reviewed for the post-transplant occurrence of infection caused by the yeast Malassezia furfur. Six patients, ranging in age from 1 to 54 years, developed Malassezia infections at a median of 59 days post transplant. Five patients were allogeneic transplant recipients; the remaining patient had undergone autologous transplantation. A spectrum of clinical manifestations of Malassezia infection was seen in these patients, including infections of mucosal surfaces and the skin, in addition to catheter-related fungemia. Unlike many of the other more common opportunistic fungal infections in immunocompromised patients, neutropenia and the use of broad-spectrum antimicrobials do not appear to be significant risk factors for Malassezia infections in the BMT population. In addition, disseminated fungal infection despite the presence of fungemia is uncommon. Lastly, the outcome of Malassezia infections in these patients, whether folliculitis, mucosal infection, or fungemia, appears to be quite favorable, in contrast to the poorer outcome with many other fungal infections in BMT patients. Catheter removal and discontinuation of intravenous lipids are important for a successful outcome in fungemic cases. Bone Marrow Transplantation (2000) 26, 645-648.
Fungal infections are a major cause of morbidity and mortality in immunocompromised cancer patients, especially those who undergo BMT. [1] [2] [3] [4] [5] Although most fungal infections in the transplant population are caused by Candida and Aspergillus species, over the past decade there has been increasing recognition of other opportunistic fungi with a characteristic clinical spectrum of infection in these profoundly immunosuppressed patients. Although the genus Malassezia consists of seven species, most human infections are caused by Malassezia furfur, which includes the species previously known as Pityrosporum ovale and Pityrosporum orbicularae. [6] [7] [8] [9] Sporadic cases of fungemia, meningitis, urinary tract infection, and cutaneous infection caused by Malassezia pachydermatis have been reported. 10, 11 Malassezia sympodialis is an unusual cause of human infection. 12 These dimorphic saprophytic yeast isolates are known to have unusual lipophilic growth requirements, in that growth occurs on standard fungal media such as Sabouraud dextrose agar only when the culture medium is supplemented with a source of medium/long-chain fatty acids. Although a variety of Malasssezia infections have been reported in nonimmunocompromised patients, this fungus may also complicate the course of BMT patients, with a spectrum of manifestations in this population. We report six BMT patients who developed Malassezia infection during the post-transplant period, describe the clinical spectrum of infection, and discuss approaches to therapy.
Patients and methods
A consecutive series of 3044 patients who underwent bone marrow (autologous, allogeneic, syngeneic) or stem cell transplantation at the University of Minnesota from 1974 to April 1999 was reviewed for the occurrence of Malassezia infections in the post-transplant period. Of the transplants, 1942 were allogeneic, and 1102 were autologous. Patients were identified in chronological fashion by a unique patient number (UPN). Clinical data was obtained from review of prospectively collected information in the University of Minnesota Bone Marrow Transplant Data Base along with medical records, microbiology/surgical pathology reports, and autopsy summaries. The post-transplant period was defined as the interval from transplant (day 0) to the date of last follow-up or death. Infections were documented by histopathologic evidence of tissue invasion and/or culture isolation of the causative agent either from a sterile body fluid or biopsy material. The WBC at the time of infection was noted, as was the presence and grade of acute/chronic GVHD. Treatment data and clinical outcome were reviewed.
Microbiology
Blood for fungal blood culture was inoculated into tubes of the BACTEC system (Becton Dickinson, Cockeysville, MD, USA) to 1983, and subsequently, the Dupont Isolator System (Wampole Laboratories, Cranbury, NJ, USA) was utilized. Fungi isolated were then inoculated on to an inhibitory mold agar slant and a brain-heart infusion agar slant containing blood and antibiotics for fungal species/genus identification. Biopsy specimens submitted for fungal culture were inoculated on to four types of agar media and incubated at 37°C: sheep blood agar, inhibitory mold agar, brain-heart infusion agar with blood and antibiotics, and mycobiotic agar (containing chloramphenicol and cyclohexamide to inhibit saprophytic fungi). Malassezia was identified by characteristic microscopic morphologic findings in addition to specific fungal culture growth requirements. The thick-walled, 3-8 m in diameter yeast is round to oval, with a broad-based bud and collarette at one pole. Hyphae and pseudohyphae are usually absent in culture; however, in clinical specimens short, slightly curved septate hyphae may be seen. The yeast grows in culture in 2 to 4 days, with optimal growth at 35-37°C, but only when the culture medium is supplemented with sterile olive oil, lanolin, or Tween 80, as a source of fatty acids. If Malassezia is suspected based upon the typical yeast appearance from initial blood culture isolation, the media of all subsequent cultures (subculture from the positive blood culture bottle for fungal isolation/identification, catheter tip cultures, etc) are supplemented with a fatty acid source. Typical colonies are smooth, glistening, and creamcolored. The yeast will assimilate dextrose, but not other sugars. It is nonfermentative and urease positive.
Histology
Tissue biopsies were stained with hematoxylin and eosin in standard fashion. When fungal infection was suspected, additional sections were stained with Gomori-methenamine-silver and periodic acid-Schiff stains to highlight fungal elements.
Results

Clinical presentation
Over the 25-year period from 1974 to April 1999, 3044 patients underwent BMT at the University of Minnesota. Six of these patients (0.002%) developed Malassezia infections at a median of 59 (range 1-114) days post BMT. The clinical characteristics of these patients and their infections are summarized in Table 1 . Only one patient was neutropenic (ANC Ͻ 500 cells/l) at time of infection. No patients had relapse of their primary disease at infection diagnosis.
Sites of infection were skin (n = 3), blood (n = 2) and vulva (n = 1). In one patient with cutaneous involvement (UPN 860), a culture of inflamed scrotal skin at day 1 post transplant when the patient was neutropenic and had a lowgrade fever revealed a heavy growth of M. furfur. The other two patients with skin infection (UPN 1321 and 2638) presented with multiple small erythematous papules in a follicular distribution after neutrophil engraftment; subsequent punch biopsies of the involved area revealed histopathologic changes consistent with Pityrosporum folliculitis. The patient with vulvar infection (UPN 1423) presented with a vulvar discharge, low-grade fever, and non-erythematous vulvar mucosa at day 58 post transplant. Malassezia furfur grew from a vulvar swab culture. This patient's hyperalimentation had been discontinued 1 day prior to infection diagnosis. Both patients with Malassezia furfur fungemia presented late in the post-tranplant course (days 94, 114), and had neutrophil engraftment for 2 to 3 months prior to infection. One (UPN 1101) was on hyperalimentation including intravenous intralipids, and developed intermittent low-grade fevers of unclear etiology.
In both of these fungemic patients, physical examination was unremarkable; specifically, no rash or hepatosplenomegaly, was present.
Risk factors, therapy and outcome
All six patients had central venous access devices (CVAD) in place. Two patients (UPN 1101, 1423) had been receiving hyperalimentation immediately prior to or at the time of fungal infection diagnosis. In all cases, there was no evidence of local infection at the catheter site. At time of infection diagnosis, all patients were on antifungal prophylaxis (either clotrimazole troches or nystatin swish and swallow). In the patients with Malassezia fungemia, the CVAD was removed, one at the time the positive blood culture was identified, and the other after several days of intermittent fungemia. Culture of the catheter tip was negative for fungal growth in both cases. Subsequent fungal blood cultures drawn after CVAD removal were negative. No patients received systemic antifungal therapy. The patient with scrotal involvement was treated successfully with topical nystatin powder. Topical ketoconazole resulted in resolution of infection in the other cases of cutaneous infection. The vulvar discharge in the remaining patient was self-limited, resolving without antifungal therapy.
Discussion
Malassezia furfur is one of the more common noncandidal yeasts causing a variety of infections, more often in normal than immunocompromised patients. [6] [7] [8] Catheter-related fungemia or folliculitis is most common, although Malassezia has been infrequently implicated as the causative agent of peritonitis, septic arthritis, mastitis, sinusitis, and various ocular infections. Malassezia may be a less virulent pathogen than Candida, with infection eradicated with antifungal therapy and/or catheter removal, even in immunocompromised patients such as BMT recipients. A spectrum of Malassezia infections was seen in our BMT recipients.
Catheter-related fungemia with Malassezia occurred in two BMT patients, both with a CVAD. Other than fever, neither patient had physical examination findings compatible with disseminated infection. Resolution of fungemia followed removal of the CVAD in each case. Catheter-associated Malassezia fungemia has been most commonly reported in the setting of premature infants with multiple medical problems, in which hyperalimentation including parenteral lipid emulsions has been administered via a CVAD, but may also occur in adults. 6, 7, [13] [14] [15] [16] [17] [18] [19] [20] This fungus colonizes the skin of affected patients, from which it may gain access to a CVAD. The spectrum of infection ranges from asymptomatic catheter colonization to fungemia with vascular involvement and a fatal outcome. Fever, usually low-grade, is present in most cases, with respiratory distress also common. As in our BMT patients, physical examination is generally unremarkable. In fatal cases from which autopsy data were available, yeasts have been found in blood vessels of numerous parenchymal organs such as lung, liver, spleen and brain. 17 As in our patient with serial positive blood cultures for Malassezia, the presence of yeasts in the peripheral blood smear was also reported in a neutropenic child who developed Malassezia furfur fungemia following BMT. 21 Resolution of infection followed CVAD removal and discontinuation of parenteral nutrition including intralipids, plus systemic antifungal therapy with growth factor support.
Our remaining four BMT patients had cutaneous or mucosal Malassezia infections. Pityriasis (tinea) versicolor, which consists of hypo-or hyper-pigmented skin lesions with thin scales that tend to be truncal in location, is the most common cutaneous infection caused by Malassezia. 7 Conditions such as diabetes, Cushing's syndrome, pregnancy, chronic renal failure, Hodgkin's disease, transplantation, trauma, neonatal status, corticosteroid therapy, and prolonged broad-spectrum antimicrobial administration may predispose to Malassezia folliculitis. 7, [22] [23] [24] [25] Lesions,
Bone Marrow Transplantation most often on the trunk and upper arms, begin as inflamed hair follicles and evolve to small, erythematous, pruritic papules or pustules. Crusting and healing generally follow in 3 to 5 days. A series of six allogeneic BMT recipients and one acute leukemic undergoing induction chemotherapy who developed Pityrosporum folliculitis was reported by Bufill et al. 22 In contrast to our BMT cases, infection occurred early in the post-transplant period (before day 18 post transplant) in the setting of neutropenia, and resolved with neutrophil engraftment in all cases. The differential diagnosis of folliculitis in BMT patient includes Candida folliculitis, 26 often a manifestation of disseminated candidal infection, in addition to GVHD. Biopsy of involved lesions may reveal yeast forms with both types of fungal folliculitis; however, no hyphal or filamentous forms will be found in cases caused by Malassezia. Fungal culture will provide definitive identification of the causative yeast. Lastly, Malassezia has also been recognized as an etiologic agent of seborrheic dermatitis occurring in HIV patients, 27, 28 in addition to nonfollicular pustulosis of the newborn. 29 Because Malassezia infections are uncommon in BMT patients, the relationship of prophylactic antifungal therapy to the development of subsequent infection is not clear. In all our patients, the sole antifungal prophylaxis was topical; no systemic prophylactic antifungal agents such as fluconazole or amphotericin B were utilized. In Bufill's cases of Pityrosporum folliculitis, the specific antifungal prophylaxis was not reported, although all patients were receiving broad-spectrum antibiotics. 22 The treatment approach to Malassezia infections, especially fungemia, has unique aspects compared to other fungi. In contrast to candidal fungemia, which may also be catheter-related, key aspects in the eradication of Malassezia fungemia are both discontinuation of lipid infusions and CVAD removal. The role of systemic antifungal agents such as amphotericin B, lipid formulations of amphotericin, or fluconazole in the therapy of these infections is much less clear than in candidal fungemia. Infections in all of our patients resolved without the use of systemic antifungal therapy. Malassezia exhibits in vitro susceptibility to imidazole derivatives such as ketoconazole; it is moderately susceptible to amphotericin B, and typically resistant to flucytosine. As Malassezia fungemia is relatively uncommon, definitive antifungal therapeutic recommendations cannot be made. Specifically, the need for parenteral antifungal therapy after CVAD removal is not known, and the optimum dose and duration of such therapy is even less clear. Treatment of cutaneous infection is generally with topical antifungal agents. In cases of Pityrosporum folliculitis previously reported in BMT recipients, skin lesions responded to prolonged topical antifungal therapy; in addition, neutrophil recovery was essential for resolution of infection. 22 For more severe or refractory cases of folliculitis, systemic agents such as ketoconazole may be employed. 6, 30, 31 
